These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37816331)

  • 1. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
    Pan Y; Zhang JT; Gao X; Chen ZY; Yan B; Tan PX; Yang XR; Gao W; Gong Y; Tian Z; Liu SM; Lin H; Sun H; Huang J; Liu SY; Yan HH; Dong S; Xu CR; Chen HJ; Wang Z; Li P; Guan Y; Wang BC; Yang JJ; Tu HY; Yang XN; Zhong WZ; Xia X; Yi X; Zhou Q; Wu YL
    Cancer Cell; 2023 Oct; 41(10):1763-1773.e4. PubMed ID: 37816331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
    Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS
    Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
    Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
    Moding EJ; Liu Y; Nabet BY; Chabon JJ; Chaudhuri AA; Hui AB; Bonilla RF; Ko RB; Yoo CH; Gojenola L; Jones CD; He J; Qiao Y; Xu T; Heymach JV; Tsao A; Liao Z; Gomez DR; Das M; Padda SK; Ramchandran KJ; Neal JW; Wakelee HA; Loo BW; Lin SH; Alizadeh AA; Diehn M
    Nat Cancer; 2020 Feb; 1(2):176-183. PubMed ID: 34505064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
    Li FQ; Cui JW
    Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
    Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
    Peled N; Roisman LC; Levison E; Dudnik J; Chernomordikov E; Heching N; Dudnik E; Keren-Rosenberg S; Nechushtan H; Salhab A; Hershkovitz D; Tsuriel S; Hannes V; Rotem O; Lazarev I; Lichtenberg R; Granot IS; Krayim B; Shalata W; Levin D; Krutman Y; Allen AM; Blumenfeld P; Lavrenkov K; Kian W
    Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):105-114. PubMed ID: 36925073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
    Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
    Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
    Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
    Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.
    Yang Y; Wang J; Wang J; Zhao X; Zhang T; Yang Y; Pang J; Ou Q; Wu L; Xu X; Xu K; Zhao J; Bai N; Yang P; Wang S; Wang L; Bi N
    Cancer Lett; 2024 Feb; 582():216569. PubMed ID: 38101608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.
    Jun S; Shukla NA; Durm G; Hui AB; Cao S; Ganti AK; Jabbour SK; Kunder C; Alizadeh AA; Hanna NH; Diehn M
    J Thorac Oncol; 2024 Jul; ():. PubMed ID: 38971369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC).
    Chen K; Zhao H; Shi Y; Yang F; Wang LT; Kang G; Nie Y; Wang J
    Clin Cancer Res; 2019 Dec; 25(23):7058-7067. PubMed ID: 31439586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer.
    Marinello A; Tagliamento M; Pagliaro A; Conci N; Cella E; Vasseur D; Remon J; Levy A; Dall'Olio FG; Besse B
    Cancer Treat Rev; 2024 Sep; 129():102791. PubMed ID: 38963991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
    J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
    Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
    Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
    Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
    BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.
    Qiu B; Guo W; Zhang F; Lv F; Ji Y; Peng Y; Chen X; Bao H; Xu Y; Shao Y; Tan F; Xue Q; Gao S; He J
    Nat Commun; 2021 Nov; 12(1):6770. PubMed ID: 34799585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.